Harderwijk, the Netherlands, April 25, 2014
Today, Dutch Software Company GENALICE announced that it has reached an agreement on a multi-million euro capital investment from Redbrae, a consortium of US- and UK-based private equity investors. The investment consortium has a strong network in the United States, United Kingdom and Middle East. It has been working with GENALICE for the past year. The successful validation and launch of GENALICE MAP, the company’s groundbreaking DNA data processing solution, formed the basis for the latest financial injection that will provide significant backing to accelerate further product development and distribution.
Lead investor Zaheer Sardar, comments: “With the successful validation of GENALICE MAP, we really have found a major game changer in the field of genomics. Big data analysis is a critical problem in this area, and we are delighted to back a company that has developed an innovative product resulting in greater accuracy, improved speed and lower costs. Our investment will contribute to accelerating this exciting phase of the GENALICE story.”
During a 24-hour webcast in December 2013, GENALICE showcased MAP’s robustness and spectacular performance. The product is up to 100 times faster than conventional tools on commodity hardware. Hans Karten, GENALICE’s CEO/CTO, adds: “Our MAP product is based on several technical innovations and is a leap forward for researchers demanding high-quality and cost-effective DNA data processing. With the advent of the $1,000 genome, GENALICE provides a correspondingly low-cost data processing and storage solution, available immediately. We view this as a very positive outcome for users of Illumina X Ten sequencing machines, as GENALICE provides a highly efficient IT solution to deal with massive data-file production. For example, GENALICE’s XS model is capable of processing data at a speed that can exceed the maximum throughput of an ultra-high-throughput sequencer; the Illumina X Ten farm, which can process 18,000 full genomes per year. But our sequence alignment and variant calling solution offers so much more than ultra-fast processing of NGS data. GENALICE MAP truly raises NGS data processing and analysis to a new level of performance, with world-beating accuracy, significant storage cost reductions, full compatibility with other pipelines and excellent user-friendliness. GENALICE provides a comprehensive solution to the analysis speed and file-size problem in a single product, so researchers can move straight to the science and concentrate on solving genetic problems.”
GENALICE MAP is already being evaluated and installed by high-volume NGS centers, institutes and companies around the world. Karten states: “We have been greatly encouraged by real-world results which are proving to be the breakthrough that our models had forecast. It is no surprise that some of the early Illumina HiSeq X Ten customers are already users of MAP. We welcome further enquiries from organizations engaged in genomic data analysis so they can see the results for themselves, in their own environment and under their own conditions. We would be prepared to discuss evaluation kits for qualified prospects, as we believe the solution will quickly prove its value.”
GENALICE is a privately owned, innovative software company, based in the Netherlands. It designs and builds groundbreaking software solutions for cost effective and accurate DNA data processing on commodity hardware. Its mission is to save lives and improve the quality of life of people with complex DNA-related diseases, such as cancer. With state of the art technology GENALICE wants to make an important contribution to improved drug development, diagnosis and treatment.
For more information please contact: